DENVER, Colo. (247marketnews.com) — bioAffinity Technologies (NASDAQ:BIAF) is adding another layer of protection around its most important commercial asset just as adoption of its CyPath Lung diagnostic is accelerating.
The company announced that the Japan Patent Office issued a Notice of Allowance for a patent covering a method of predicting the likelihood of lung cancer using CyPath Lung, its noninvasive test combining flow cytometry with an AI-built analysis algorithm. If issued after payment of the required fee, the patent would become the company’s latest piece of intellectual-property protection in Asia.
bioAffinity is attempting to build a proprietary platform around the early detection and risk assessment of lung disease. CEO Maria Zannes said the Japanese patent “strengthens and expands the Company’s intellectual property protection in the Asian market,” adding that the company anticipates patents in additional geographic regions.
The timing is particularly compelling. CyPath Lung test volume jumped 216% year over year in Q2 2026, while the number of physician offices and clinics ordering the test increased 122%. By July, the company said it had surpassed the total number of CyPath Lung tests completed during all of 2025, with more than 1,200 test reports delivered to physicians.
That commercial momentum follows a strong first half. CyPath Lung testing revenue rose approximately 156% to $835,000 for the first six months of 2026, compared with $323,000 during the same period of 2025.
Meanwhile, bioAffinity is widening the potential market. In September, the company announced it was advancing CyPath Lung for surveillance of lung cancer survivors, a population exceeding 680,000 Americans according to the company’s cited American Cancer Society data. The company is also developing potential diagnostic applications for asthma and COPD.
The international patent strategy adds another potentially valuable piece. The company recently received a Hong Kong patent, following earlier Chinese protection, giving CyPath Lung additional intellectual-property coverage in a region the company says accounts for nearly two-thirds of global lung cancer cases.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.